{
    "code": "60001215",
    "url": "https:\/\/info.fda.gov.tw\/MLMS\/H0001D.aspx?Type=Lic&LicId=60001215",
    "time": "2023-03-17 05:50:20",
    "許可證字號": "衛部菌疫輸字第001215號",
    "註銷狀態": "",
    "註銷日期": "",
    "註銷理由": "",
    "製造許可登錄編號": "",
    "有效日期": "117\/02\/01",
    "發證日期": "112\/02\/01",
    "許可證種類": "菌　疫",
    "舊證字號": "",
    "醫療器材級數": "",
    "第一等級醫療器材原登錄字號": "",
    "第一等級醫療器材新登錄字號": "",
    "通關簽審文件編號": "DHA06000121505",
    "中文品名": "泰莎樂注射液劑210毫克",
    "英文品名": "TEZSPIRE Solution for Injection 210 mg",
    "適應症": "12歲以上嚴重氣喘病人的附加維持治療(add-on maintenance therapy)。使用限制：不適用於緩解急性支氣管痙攣或重積性氣喘(status asthmaticus)。",
    "劑型": "27D注射液劑",
    "包裝": "玻璃預填式注射器，每支1.91毫升、100支以下盒裝 預填式注射筆，每支1.91毫升、100支以下盒裝",
    "儲存溫度": "",
    "有效期間": "",
    "指示藥品審查基準": "",
    "標籤、仿單及包裝加註": "",
    "藥品類別": "05限由醫師使用",
    "管制藥品分類級別": "",
    "藥品分類": "基因工程產品_新成分",
    "監視期限": "117\/02\/01",
    "主成分略述": "Tezepelumab",
    "限制項目": "02輸　入 5F免除銜接性試驗",
    "申請商名稱": "1434901100  臺灣阿斯特捷利康股份有限公司",
    "申請商地址": "台北市大安區敦化南路二段207號21樓",
    "主製造廠": [
        {
            "製造廠名稱": "FPR0034000  AMGEN MANUFACTURING,LIMITED",
            "製造廠廠址": "STATE ROAD 31,KM 24.6 JUNCOS,PUERTO RICO 00777-4060",
            "製造廠公司地址": "",
            "製造廠國別": "PUERTO RICO",
            "製程": ""
        }
    ],
    "次製造廠": [
        {
            "製造廠名稱": "FUS0325000  AMGEN INC.",
            "製造廠廠址": "ONE AMGEN CENTER DRIVE THOUSAND OAKS CA 91320-1799 U.S.A.",
            "製造廠公司地址": "",
            "製造廠國別": "UNITED STATES",
            "製程": "原料藥製造廠"
        }
    ],
    "CCC號列": "",
    "藥理治療分類": "",
    "ingredients": [
        {
            "成分類別": "主成分",
            "成分代碼": "9200040300",
            "成分名稱": "Tezepelumab",
            "含量描述": "",
            "含量": "210.0000000000",
            "單位": "MG"
        }
    ]
}